---
title: "Obefazimod (ABX464) in Ulcerative colitis: Pathophysiology"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Pathophysiology. Topics: Overview: barrier disruption, dysbiosis, and abnormal mucosal immune activation; Mucosal inflammation: continuous from the rectum and limited to the mucosa; Epithelial barrier: impaired barrier and UC-specific epithelial susceptibility genes; Microbiota: reduced diversity and loss of short-chain fatty acid producers; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Overview: barrier disruption, dysbiosis, and abnormal mucosal immune activation

> “A widely accepted framework suggests a complex contribution of environmental and host factors that increase the susceptibility of developing UC, and disease onset is triggered by events that perturb the mucosal barrier, alter the healthy balance of the gut microbiota, and abnormally stimulate gut immune responses.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “Ulcerative colitis is thought to occur in people with a genetic predisposition following environmental exposures; gut epithelial barrier defects, the microbiota, and a dysregulated immune response are strongly implicated.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

<a id="topic-2.2.1.4-2"></a>

### Mucosal inflammation: continuous from the rectum and limited to the mucosa

> “These clinical features include the almost-universal involvement of the rectum (the lowest part of the colon) as the first site where inflammation starts and the distinctively confluent nature of inflammation that ends with an abrupt demarcation and transition into normal colonic mucosa.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “The disease causes long-lasting inflammation and ulcers in the digestive tract and is typically marked by periods of remission and recurrence of symptoms.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.4-3"></a>

### Epithelial barrier: impaired barrier and UC-specific epithelial susceptibility genes

> “An impaired epithelial barrier is a pathogenic factor for UC”
> “UC-specific genes implicate epithelial dysfunction”
> “With the histologic observation of subepithelial inflammation, many studies implicate an impaired epithelial barrier as a pathogenic factor for UC.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

<a id="topic-2.2.1.4-4"></a>

### Microbiota: reduced diversity and loss of short-chain fatty acid producers

> “The UC gut microbiome, virome, and mycobiome is less diverse over time”
> “A depletion of protective bacteria such as short-chain fatty acid (SCFA)-producing Ruminococcaceae and Lachnospiraceae that coincides with an expansion of pro-inflammatory microbes such as Enterobacteriaceae, including Escherichia coli, and Fusobacteriaceae has been noted 37, 38.”
> “It is not known if dysbiosis is a consequence of, or plays a causal role in, gut inflammation in UC.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

<a id="topic-2.2.1.4-5"></a>

### Immune response: innate activation, atypical Th2 response, and IL-23 and Th17 pathways

> “Innate immune responses (neutrophils/macrophages) may promote a pathogenic adaptive (likely T-cell driven) response”
> “Traditionally, UC is associated with a Th2 response with high IL-4, IL-5, and IL-13, whereas CD has a more dominant Th1/Th17 response 84.”
> “These include the identification of IL-23 as a key driver of Th17 responses 86, genetic associations with IL-23 and its related genes 11, 87, and the presence of Th17 88 (and Th9 89) cells in UC.”
> “Blocking IL-23, however, is effective in UC, e.g. mirikizumab (anti-p19 subunit of IL-23) 92 and ustekinumab (anti-p40 subunit of IL-23) 93.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “An improved understanding of the mechanisms underlying UC has led to the emergence of new treatments.”

Source: [Kobayashi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32913180/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
